跳至主要内容
临床试验/EUCTR2018-003630-33-GB
EUCTR2018-003630-33-GB进行中(未招募)1 期

Spironolactone for Adult Female Acne: A pragmatic multicentre double-blind randomised superiority trial to investigate the clinical and cost-effectiveness of spironolactone for moderate or severe persistent acne in women - Spironolactone for Adult Female Acne

niversity of Southampton0 个研究点目标入组 434 人开始时间: 2019年11月8日最近更新:
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
入组人数
434

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
Female

入选标准

  • - Women aged 18 years or over
  • - Facial acne, symptoms present since at least 6 months
  • - Acne of sufficient severity to warrant treatment with oral antibiotics, as judged by the study clinician
  • - Women of childbearing potential at risk of pregnancy must be willing to use their usual hormonal or barrier method of contraception for the first 6 months of the study
  • - Willing to be randomised to either study group
  • - Willing and able to give informed consent
  • - Sufficient English to carry out primary outcome Acne-QoL (which has not been validated in other languages)
  • Are the trial subjects under 18? no
  • Number of subjects for this age range: 0
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 433
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 1

排除标准

  • - Serum potassium above the upper limit of the reference range for the laboratory processing the test (measured at the baseline clinic visit)
  • - eGFR below 60 ml/min/1.73m2
  • - Hereditary problems of galactose intolerance, lactase deficiency or glucose-galactose malabsorption
  • - Acne grade 0-1 using the Investigator’s Global Assessment (i.e. clear or almost clear)
  • - Currently taking potassium-sparing diuretic, ACE inhibitor, angiotensin II receptor blocker or digoxin
  • - Started, stopped or changed long-term (lasting more than 2 weeks) hormonal contraception, co-cyprindiol or other hormonal treatment within the past 3 months
  • - Planning to start, stop or change long-term hormonal contraception, co-cyprindiol or other hormonal treatment within the next 3 months
  • - Pregnant/breastfeeding
  • - Intending to become pregnant in the next 6 months
  • - Androgen-secreting adrenal or ovarian tumour
  • - Cushing’s syndrome
  • - Congenital adrenal hyperplasia
  • - Oral antibiotic treatment (lasting longer than a week) for acne within the past month
  • - Oral isotretinoin treatment within the past 6 months

研究者

发起方
niversity of Southampton

相似试验